Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment:A case report
作者机构：Division of Hepato-Biliary-Pancreatic Surgery and Transplant SurgeryDepartment of SurgeryAsahikawa Medical UniversityAsahikawa 078-8510HokkaidoJapan Department of GastroenterologyAsahikawa-Kosei General HospitalAsahikawa 078-8211HokkaidoJapan
出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)
年 卷 期：2020年第12卷第12期
页 面：1349-1357页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Conversion to surgery Lenvatinib Recurrent hepatocellular carcinoma Case report Neoadjuvant therapy Molecular targeted therapy
摘 要：BACKGROUND Lenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients with unresectable hepatocellular carcinoma(HCC)who have not received prior systemic *** patients treated with lenvatinib,40%of cases achieved sufficient tumor reduction to make potential surgery ***,the outcomes of such surgery are *** report a successful case of hepatic resection for recurrent HCC after lenvatinib *** SUMMARY A 69-year-old man underwent right anterior sectionectomy for HCC in segment 8 of the *** months later,he was found to have an intrahepatic HCC recurrence that grew rapidly to 10 cm in diameter with sternal bone *** confirming partial response to lenvatinib administration for 2 mo,a second hepatectomy was *** examination showed that 80%of the tumor was *** patient did not develop any adverse effects under lenvatinib *** was discharged at 25 d after *** therapy for bone metastases continued to be given under lenvatinib,and the patient has remained alive for 1 year after the second *** The prognosis of patients with recurrent HCC may be improved by liver resection combined with prior lenvatinib therapy.
维普期刊数据库